How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: In the BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) trial involving 7,020 patients with type 2 diabetes and established cardiovascular (CV) disease, empagliflozin given in addition to standard of care reduced the risk of CV death by 38% versus placebo (hazard ratio [HR] 0.62 [95% CI 0.49, 0.77]). This exploratory mediation analysis assesses the extent to which treatment group differences in covariates during the trial contributed to CV death risk reduction with empagliflozin. RESEARCH DESIGN AND METHODS: Effects of potential mediators, identified post hoc, on the HR for CV death with empagliflozin versus placebo were analyzed by Cox regression models, with treatment group adjusted for the baseline value of the variable and its change from baseline or updated mean (i.e., considering all prior values), each as a time-dependent covariate. HRs were compared with a model without adjustment for covariates. Multivariable analyses also were performed. RESULTS: Changes in hematocrit and hemoglobin mediated 51.8% and 48.9%, respectively, of the effect of empagliflozin versus placebo on the risk of CV death on the basis of changes from baseline, with similar results in analyses on the basis of updated means. Smaller mediation effects (maximum 29.3%) were observed for uric acid, fasting plasma glucose, and HbA1c. In multivariable models, which incorporated effects of empagliflozin on hematocrit, fasting glucose, uric acid, and urine albumin:creatinine ratio, the combined changes from baseline provided 85.2% mediation, whereas updated mean analyses provided 94.6% mediation of the effect of empagliflozin on CV death. CONCLUSIONS: In this exploratory analysis from the EMPA-REG OUTCOME trial, changes in markers of plasma volume were the most important mediators of the reduction in risk of CV death with empagliflozin versus placebo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“both have been identified as important determinants of the heart failure benefits of these drugs in trials of patients with type 2 diabetes.”
From Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial (2021) · cites this paper as [32]
In the citing paper
“Those that appear particularly plausible include effects on volume status, natriuresis, expansion of red blood cell mass, and myocardial energetics (34,36,59,62,64).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [59]
In the citing paper
“Thus, the mechanisms by which SGLT2 inhibitors reduce the risk for HF are not attributable to improved glycemic control (59).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [59]
Citations
Cites
Baron, R. M., & Kenny, D. A. (1986) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.51.6.1173 · Cited by 91,532 · cited 2×
“A traditional mediation analysis as originally proposed by Baron and Kenny (12) was used, taking the time-dynamic evolvement of both the potential mediators and the outcome CV death into account.”
Method(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citation10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Introduction to Statistical Mediation Analysis
MacKinnon, D. P. (2012) · doi:10.4324/9780203809556 · Cited by 5,618
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Self-citationUric Acid and Cardiovascular Risk
Feig, D. I., Kang, D.-H., & Johnson, R. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0800885 · Cited by 2,440
Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
Self-citationCherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329 · cited 1×
“Moreover, only variablesmeasured during the trial could be examined, and in addition to the potential mediators we investigated, other variables such as reductions in glomerular hyperfiltration (35), reductions in arterial stiffness and vascular resistance (36), direct cardiac effects through reductions in myocardial…”
BackgroundSelf-citationLow Wang, C. C., Hess, C. N., Hiatt, W. R., & Goldfine, A. B. (2016) · Circulation · doi:10.1161/circulationaha.116.022194 · Cited by 1,155 · cited 1×
“Therefore, many participants in this trial likely had unrecognized left ventricular dysfunction, particularly diastolic dysfunction, which may eventually lead to clinical heart failure with preserved ejection fraction (25).”
Background
Research works printed but not linked: 2
- Fitchett, Further exploration of the cardiovascular mortality reduction with empagliflozin in patients with type 2 diabetes and cardiovascular disease in EMPA-REG OUTCOME, J Am Coll Cardiol
- Boehringer Ingelheim. Empagliflozin (Jardiance®) to be studied in chronic kidney disease. 2017. Available from https://www.boehringer-ingelheim.com/press-release/empagliflozin-be-studied-chronic-kidney-disease. Accessed 6 September 2017
Cited by
Items 601–700 of 762
Li, C., Ng, J. K., CHAN, G. C., Fung, W. W., Chow, K.-M., & Szeto, C. (2025) · Clinical Nephrology · doi:10.5414/cn111700 · Cited by 1
Hori, T., Aihara, K., Kawano, Y., Watanabe, T., Kaneko, Y., Kawata, S., Shimizu, K., Hosoki, M., Mori, K., Otoda, T., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0338372 · Cited by 1
“SGLT2 is increasingly used for renal and cardiovascular protection and glycemic control, and has demonstrated a strong protective effect, partly through anemia correction [26,27].”
Bonilha, I., Yoshinaga, M. Y., Chaves‐Filho, A. B., Gomes, É. I. L., Santos, R. S., Breder, I. S. S., Breder, J. D. S. C., Miyamoto, S., Nadruz, W., Kontush, A., et al. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120686 · Cited by 1
Impact of SGLT2 Inhibitors on Multiple Cardiometabolic Risk Factors: A Retrospective Cohort Study
Işık, H., Demirdöğen, K. K., Çakır, T., Çetinkalp, Ş., Kerry, Z., & Arun, M. Z. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15072550 · Cited by 1
“SGLT2Is have also been shown to be associated with a reduction in the risk of major adverse cardiovascular events (MACEs) and to protect against cardiovascular death and death from any cause [8,9].”
Dissecting out the unexpected effects of SGLT2 inhibitors on human aging
Katsuumi, G., & Minamino, T. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag207 · Cited by 1
Bénéfices cardiovasculaires et rénaux des inhibiteurs de SGLT2 : mécanismes de la protection
Vergès, B. L., & Hadjadj, S. (2019) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(19)30062-8 · Cited by 1
Brunke-Reese, D., Ssentongo, P., Ssentongo, A. E., Phillips, B. E., Pauli, E. M., Berg, A. S., Kelleher, S. L., & Soybel, D. I. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02588 · Cited by 1
Class effect: dapagliflozin reduces cardiovascular and kidney events
Salehi, T., & Coates, P. T. (2019) · Kidney International · doi:10.1016/j.kint.2019.08.035 · Cited by 1
Mécanismes possibles des effets bénéfiques cardiovasculaires des inhibiteurs SGLT2
Vergès, B. L. (2019) · Archives of Cardiovascular Diseases Supplements · doi:10.1016/s1878-6480(19)30961-9 · Cited by 1
Imran, H. M., Nester, W. A., Elgendy, I. Y., & Saad, M. S. (2020) · Annals of Medicine · doi:10.1080/07853890.2020.1767298 · Cited by 2
“markers for plasma volume were the most important mediators for cardiovascular effects of SGLT2 inhibitors [42].”
BackgroundMüller‐Wieland, D., Schütt, K. S., Brandts, J., & Marx, N. (2020) · Herz · doi:10.1007/s00059-020-04946-8 · Cited by 1
Prescribing Paradigm Shift? Damned If You Do, Damned If You Don’t
Marx, N., & Grant, P. J. (2020) · Diabetes Care · doi:10.2337/dci20-0027 · Cited by 1
“independent of their glucose-lowering properties (15,16).”
Özışık, H., Çetinkalp, Ş., Candemir, A., Süner, A., & Nalbantgil, S. (2020) · Journal of Integrative Cardiology · doi:10.15761/jic.1000296 · Cited by 1
“SGLT2 inhibitors improved the myocardial oxygen supply because of this pathophysiological mechanism an increase in hematocrit and hemoglobin could be found [18].”
BackgroundTimar, B., Braha, A., Grigorică, L., Gaiţă, L., & Timar, R. Z. (2020) · Timişoara Medical Journal · doi:10.35995/tmj20200101 · Cited by 1
“Additionally, data from the EMPA-REGOUTCOME suggested that changes in plasma volumewere themost crucial factor in reducing the risk of cardiovascular death with empagliflozin compared to the placebo [31].”
MethodA PARADIGM SHIFT FOR THE SGLT2 INHIBITORS – TREATING THE HEART WITH ANTI-HYPERGLYCAEMIC DRUGS
Bădilă, E. (2021) · FARMACIA · doi:10.31925/farmacia.2021.5.2 · Cited by 1
“CaMKII are known mechanisms in the pathophysiology of HF, leading to contractile dysfunction and arrhythmias by increasing diastolic Ca 2+ leak from the sarcoplasmic reticulum (SR) and reducing SR Ca 2+ load [11].”
Babic, M., & van der Giet, M. (2021) · Dialyse aktuell · doi:10.1055/a-1557-3924 · Cited by 1
“[6] Inzucchi SE, Zinman B, Fitchett D et al.”
BackgroundInfluentialGitto, M., Kotinas, A. S., Terzi, R., Oliva, A., Zagoreo, J., Reimers, B., Stefanini, G. G., Mirani, M., Favacchio, G., Condorelli, G., et al. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001280 · Cited by 1
Munde, M. K., Kulkarni, N. S., Rukhe, N. B., Sen, A. K., & Sen, D. B. (2022) · INDIAN DRUGS · doi:10.53879/id.59.05.12595 · Cited by 1
Metabolic effects of empagliflozine
Кедик, А. В., & Kutsin, O. O. (2022) · Diabetes Obesity Metabolic Syndrome · doi:10.57105/2415-7252-2022-5-04 · Cited by 2
Lubberding, A. F., Holst, J. J., & Madsbad, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00017-6 · Cited by 1
Adiponectin, Diabetes, and the Cardiovascular System
Gasbarrino, K., Boutari, C., Filippaios, A., Gianopoulos, I., Daskalopoulou, S. S., & Mantzoros, C. S. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_8 · Cited by 1
Genetics of Coronary Artery Disease in Diabetes Mellitus
Morieri, M. L., & Doria, A. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_6 · Cited by 1
SGLT2 Inhibitors and GLP1 Antagonists on Diabetes and Cardiovascular Disease
FITCHETT, D. H. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_33 · Cited by 1
Self-citationGerstein, H. C., Yang, M., Lee, S. F., Branch, K. R., Prato, S. D., Lam, C. S. P., Lópes, R. D., Pratley, R. E., Rosenstock, J., & Sattar, N. A. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15957 · Cited by 1
Tassone, F., Ferreri, C., Rossi, A., Borretta, G., Pastorini, G., Anastasio, F., & Feola, M. (2025) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/0118715303372020250131060159 · Cited by 1
Murphy, P. T. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.106496 · Cited by 1
Wanner, C., von Eynatten, M., & Zinman, B. (2018) · Circulation · doi:10.1161/circulationaha.118.035881 · Cited by 1
Self-citationSocioeconomics and Atherosclerosis
Udell, J. A. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.06.018 · Cited by 1
Welcome Empagliflozin ! ASCVD, Heart Failure and CVD death
Majumder, A. A. S. (2019) · Cardiovascular Journal · doi:10.3329/cardio.v12i1.43410 · Cited by 1
Neeland, I. J., Eliasson, B., Kasai, T., Marx, N., Zinman, B., Inzucchi, S. E., Wanner, C., Zwiener, I., Wojeck, B. S., Yaggi, H. K., et al. (2020) · doi:10.2337/figshare.12970550 · Cited by 1
Self-citationPatoulias, D., Papadopoulos, C. E., & Doumas, M. N. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15382 · Cited by 1
“It should be highlighted that SUA lowering has been recognized as a significant mediator implicated into cardioprotection observed with sodium–glucose cotransporter-2 inhibitors.(4,5) Thus, it is ambiguous whether SUA lowering with GLP-1RAs could indeed confer to cardiovascular risk reduction observed with this class.”
BackgroundAch, T., Amri, F., & Mrabet, H. E. (2025) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2025.21.2.1 · Cited by 1
Cho, Y., & Kang, E. S. (2018) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2018.7.1.21
Ismail, M., Ibrahim, A. S. A., & Gamal, A. M. (2018) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000802
Słoniak, R., Tittinger, T., Szczepański, D., Gaździk, T. S., Kulesa-Mrowiecka, M., & Kikowski, Ł. (2019) · Wiadomości Lekarskie · doi:10.36740/wlek201903102
Gorb, Y. G., Strona, V. I., & Komir, I. (2020) · Ukraïnsʹkij žurnal medicini bìologìï ta sportu · doi:10.26693/jmbs05.02.018
“Отримані дані про те, що терапія селективним інгібіторомSGLT-2емпагліфлозином сприяє значному скороченню тривалості госпіталізації з приводу ХСН і зниженню ризику серцево-судинної смерті [10, 74, 75].”
Diagnostik und Therapie der chronischen Herzinsuffizienz: Update 2020
Güder, G., Ertl, G., & Angermann, C. E. (2020) · Herz · doi:10.1007/s00059-019-04877-z
The Effects and the Mechanisms of Sodium Glucose Cotransporter-2 Inhibition in Heart Failure
Gong, H. (2020) · Interventions in Obesity & Diabetes · doi:10.31031/iod.2020.03.000571
“A COX regression analysis of a large randomized controlled clinical trial of englitazone also showed that hematocrit and increased hemoglobin may be the main reasons for mediating the cardiovascular effects of empagliflozin [27].”
MethodRevisions of a Clinical Practice Guideline for Diabetes Management Protocol
Huston, D. O. (2020) · ScholarWorks (Walden University)
Kardiovaskuläre Effekte von SGLT-2-Inhibitoren
Mustroph, J., & Neef, S. (2020) · Diabetes aktuell · doi:10.1055/a-1152-2157
“[11] Inzucchi SE, Zinman B, Fitchett D et al.”
BackgroundLI, J., Neal, B. C., Heerspink, H. J. L., Arnott, C. G., Cannon, C. P., Agarwal, R., Bakris, G. L., Charytan, D. M., de Zeeuw, D., Greene, T., et al. (2020) · Diabetes · doi:10.2337/db20-1130-p
Self-citationValensi, P. E. (2020) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2020.04.015
Rieth, A. J., Hamm, C. W., Wanner, C., Mitrović, V. L., & Keller, T. (2020) · Herz · doi:10.1007/s00059-020-04994-0
Self-citationCONTROL OF CARDIOVASCULAR RISK FACTORS IN PATIENTS AFTER MYOCARDIAL INFARCTION
Pęksa, J. W., Jankowski, P., & Czarnecka, D. (2019) · Wiadomości Lekarskie · doi:10.36740/wlek201903129
Extending the use of SGLT2 inhibitors from diabetic to non-diabetic kidney disease
Dekkers, C. C. J. (2020) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.136049658
Koomen, J. V. (2021) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.154332602
Mason, T. (2020) · TSpace (University of Toronto)
Morales-Villegas, E., Castillo-Núñez, Y., & Castillo, G. A. (2021) · Medical Research Archives · doi:10.18103/mra.v9i6.2442
Vowel Shift in Northern New Mexico Chicano English
Ho, J. (1993) · Mester
Tanaka, A., Imai, T., Suzuki, M., Hiramitsu, S., Takahashi, N., Kadokami, T., Kiyosue, A., Nishino, M., Sakata, Y., Node, K., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14656
“REG OUTCOME trial showed that changes in markers of volume status were the strongest mediators of the reduction in the risk of adverse outcomes with SGLT2i treatment.(9,10) In the CANDLE trial,”
BackgroundSGLT2 inhibitors: a promising class of antidiabetic agents
Diaconu, C. C. (2018) · Archives of the Balkan Medical Union · doi:10.31688/abmu.2018.53.4.485
Neeland, I. J., Eliasson, B., Kasai, T., Marx, N., Zinman, B., Inzucchi, S. E., Wanner, C., Zwiener, I., Wojeck, B. S., Yaggi, H. K., et al. (2020) · doi:10.2337/figshare.12970550.v1
Self-citationEmpagliflozin as a part of optimal medical therapy for chronic heart failure
Uskach, T. M. (2022) · Russian Cardiology Bulletin · doi:10.17116/cardiobulletin20221702116 · Cited by 1
SGLT-2 inhibitors: new effective drugs for treatment of heart failure
KRÓL, O., Gładysz, K., Szydłowska, J., ŻUCHNIK, O., Kwiatkowski, P., Czelej, M., KŁOS, A., GIEROBA, K., Szydłowski, M., & Zuchniak, P. (2022) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.13.02.007
der Beek, A. B. V. D. A. (2023) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.637600695
Borges, F. A. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2023.tde-16062023-110249
Docherty, K. F. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.08.013
Effects of Sglt2 Inhibitors on The Heart
ABDELBAKI, M., & Baghous, H. (2023) · Clinical Medicine And Health Research Journal · doi:10.18535/cmhrj.v3i6.274
“This "diuretic" effect is likely to partially explain the cardiovascular benefit of SGLT2 inhibitors, as indicated by data from the EMPA-REG OUTCOME study showing that part of the cardiovascular effects of empagli-flozin is associated with induced hemoconcentration [7].”
ResultInibitori del cotrasportatore sodio-glucosio di tipo 2 in pazienti sottoposti a trapianto renale
Tsalouchos, A. (2023) · Giornale di Clinica Nefrologica e Dialisi · doi:10.33393/gcnd.2023.2620
“Le analisi post hoc dello studio EMPAREG OUTCOME hanno mostrato che l’aumento dell’e - matocrito era associato a una protezione cardiovascolare (56).”
BackgroundDiabetes, prediabetes, and heart failure
Rosano, G. M. C., Butler, J., Seferovic, P. M., Seferović, J. P., & Cosentino, F. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780198891628.003.0073
Research Progress on the Protective Mechanism of Dapagliflozin on Cardiovascular System
米, 颖. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.13122857
Reverzibilis polyglobulia SGLT-2-gátló-kezelés elhagyását követően – esetbemutatás
Márkus, B., Wittmann, I., & Laczy, B. (2023) · Diabetologia Hungarica · doi:10.24121/dh.2023.28
Mediators of Cardiovascular and Renal Outcomes: How Do Novel Diabetes Medications Work?
Dakroub, A. H., & Almarzooq, Z. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.033863
“4,5 Although these studies have provided some suggested mediators, a more comprehensive analysis with greater generalizability is needed to confirm these findings.”
BackgroundThe Role of Uric Acid in Hypertension and Heart Failure
Borghi, C., Adorno, A., Gallelli, I., & Dall’Olio, M. (2023) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-39315-0_10
Viñoles, F. C., Avila, J. R., Santiago, D., Vilera, N., Réquiz, Z. A., & Camperos, P. (2023) · Diabetes actual · doi:10.61156/2023.1.1.001
EFFECT OF GLIFLOZINS ON RENAL DYSFUNCTION IN CHRONIC HEART FAILURE WITH ANEMIA
Gadaev, A. G., & Khujakulova, F. I. (2023) · Oriental Journal of Medicine and Pharmacology · doi:10.37547/supsci-ojmp-03-04-10
Highlights of the 2023 Brano Heart Failure Forum
Merkely, B. P., Radovancevic, R., Vrtovec, B., & Gregorič, I. D. (2024) · The VAD Journal · doi:10.58464/2378-2706.1064
IS EMPAGLIFLOZIN A NEW DRUG IN THE MAKING FOR PATIENTS WITH ACUTE DECOMPENSATED HEART FAILURE?
Iqbal, N., Qureshi, M. A., Latif, M. Z., Bhatti, M. I., Abdullah, H. A., & Tahir, S. (2024) · JAIMC Journal of Allama Iqbal Medical College · doi:10.59058/jaimc.2023.21.4.292
Approche de la décision partagée concernant la prise en charge du diabète de type 2
MacDonald, B. J., McCormack, J. P., & Turgeon, R. D. (2024) · Canadian Family Physician · doi:10.46747/cfp.7005316 · Cited by 1
Koshino, A. (2024) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.1034863022
“(83-85) The increase in hematocrit and hemoglobin with SGLT2 inhibitors could be partially attributed to their diuretic effect.”
BackgroundLauretti, C. (2024) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2024.tde-09102024-145722
Denda, N., Maletin, N., Atanasković, M., Vučković, B., & Rašković, A. (2024) · Hospital Pharmacology - International Multidisciplinary Journal · doi:10.5937/hpimj2403483d
Tratamento da Insuficiência Cardíaca com Inibidores de SGLT2: Uma Revisão Sistemática com Metanálise
Peres-Filho, F. P., da Silva, S. U., Peres, F. P., & Kerche, L. E. (2024) · ABC Heart Failure & Cardiomyopathy · doi:10.36660/abchf.20240060
Grillet, P.-E. (2022) · theses.fr (ABES) · doi:10.70675/abe6b36az8529z451azaa56z68fa7eb7fae5
Masi, S., Dalpiaz, H., & Savarese, G. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.11.049
Li, P., Wang, X., & Li, L. (2025) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s497413
Reviews in Frontiers in Nephrology
(2025) · Frontiers research topics · doi:10.3389/978-2-8325-6101-0
INNOVATIVE DEVELOPMENT MODELS: TRENDS AND INNOVATIONS
International Science Group, & Vladlenov, D. (2025) · doi:10.46299/isg.p.2025.1.16
Silveira, M. D. S. (2024) · VITTALLE - Revista de Ciências da Saúde · doi:10.63595/vittalle.v36i2.16088
“Outro efeito adverso importante é a depleção de volume, que pode resultar em hipotensão, especialmente em pacientes idosos ou aqueles com função renal comprometida (43).”
Belal, A., Suresh, S., & Sayrafizadeh, F. (2025) · International Journal For Multidisciplinary Research · doi:10.36948/ijfmr.2025.v07i04.51363
Olabode, O., Agunbiade, A., Bhatt, J., Asasfeh, E., & Misir, A. (2025) · International Journal For Multidisciplinary Research · doi:10.36948/ijfmr.2025.v07i04.51435
Pleiotropic Effects of Renal Disease Management: Role of SGLT2 Inhibitors
Calderón-Lojero, I. O., Valdez-Ortiz, R., & Sanchez-Pozos, K. A. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815305692125010018
Huang, W., Kimmel, S. E., Ahmed, M. M., Smith, S. M., Lee, Y. A., Yang, L., Hernandez, I., Bian, J., & Guo, J. S. (2025) · JMIR Formative Research · doi:10.2196/71595
“Such contextual factors are increasingly recognized to influence health outcomes and serve as a critical source of information to develop policy interventions designed to improve population health management and value-based care [14,15].”
Chichagi, F., Meftah, E., Rahmati, R., Zarimeidani, F., Tavasol, A., Mardasi, K. G., & Omidi, N. (2025) · Current Cardiology Reviews · doi:10.2174/011573403x377983250904004839
“Furthermore, the diuretic properties of SGLT2 inhibitors can diminish preload, hence reducing the myocardial oxygen demand for blood circulation and alleviating congestion [60-64].”
La néphropathie diabétique : qu’est-elle devenue en 2025 ?
Marre, M. (2025) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2025.09.003
Murashima, M., Suzuki, K., Kasugai, T., Miyaguchi, Y., Hiratsuka, M., Tomonari, T., Ono, M., Mizuno, M., Tanaka, T., & Hamano, T. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70189
Plasma volume status in type 2 diabetes and its association with antidiabetic therapy
Cutruzzolà, A., Vescio, F., Massaro, M. R., Torcasio, G., Gnasso, A., & Irace, C. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-03015-w
“In a post hoc mediation analysis from the EMPA-REG OUTCOME trial, the reduction in haematocrit, expression of PV contraction due to the diuretic properties of SGLT2i, was the principal component of the benefits of empagliflozin [19].”
Shimizu, W., Kubota, Y., Hoshika, Y., Mozawa, K., Tara, S., Tokita, Y., Yodogawa, K., Iwasaki, Y., Yamamoto, T., Takano, H., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13010690
Li, M., Yi, T., Fan, F., Qiu, L., Wang, Z., Weng, H., Ma, W., Zhang, Y., & Huo, Y. (2022) · Figshare · doi:10.6084/m9.figshare.20374618
Liu, J., Chang, X., Ding, X., He, X., Wang, J., & Wang, G. (2024) · Figshare · doi:10.6084/m9.figshare.26648916
Liu, J., Chang, X., Ding, X., He, X., Wang, J., & Wang, G. (2024) · Figshare · doi:10.6084/m9.figshare.26648943
Liu, J., Chang, X., Ding, X., He, X., Wang, J., & Wang, G. (2024) · Figshare · doi:10.6084/m9.figshare.26648934
Liu, J., Chang, X., Ding, X., He, X., Wang, J., & Wang, G. (2024) · Figshare · doi:10.6084/m9.figshare.26648922
Shimizu, W., Kubota, Y., Hoshika, Y., Mozawa, K., Tara, S., Tokita, Y., Yodogawa, K., Iwasaki, Y., Yamamoto, T., Takano, H., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13010693
Additional file 1 of Effect of high-fat diet and empagliflozin on cardiac proteins in mice
Pan, X., Chen, S., Chen, X., Ren, Q., Yue, L., Niu, S., Li, Z., Zhu, R., Chen, X., Jia, Z., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21341089
Liu, J., Chang, X., Ding, X., He, X., Wang, J., & Wang, G. (2024) · Figshare · doi:10.6084/m9.figshare.26648949
Metadata
- Authors
- Inzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., Schmoor, C., Ohneberg, K., Johansen, O. E., George, J. T., Hantel, S., Bluhmki, E., & Lachin, J. M.
- Affiliations
- Yale University (US)
- Mount Sinai Hospital (CA)
- St. Michael's Hospital (CA)
- Universitätsklinikum Würzburg (DE)
- Istituto di Fisiologia Clinica (IT)
- University of Freiburg (DE)
- Boehringer Ingelheim (Norway) (NO)
- Boehringer Ingelheim (Germany) (DE)
- George Washington University (US)
- Corresponding author
- Inzucchi, Silvio E.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-12-04
- Volume
- 41
- Issue
- 2
- Pages
- 356-363
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2772204795
- Cited by
- 740
- References
- 33
- Citations by year
- 2026: 33 · 2025: 48 · 2024: 71 · 2023: 83 · 2022: 103 · 2021: 109 · 2020: 139 · 2019: 96 · 2018: 56
- FWCI
- 62.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Eisai
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- empagliflozin, cardiovascular mortality, mediation analysis, type 2 diabetes, EMPA-REG OUTCOME trial, hematocrit, hemoglobin, plasma volume, uric acid, fasting blood glucose, HbA1c, urine albumin-creatinine ratio, SGLT2 inhibitors
- MeSH terms
- Adult, Aged, Benzhydryl Compounds, Blood Glucose, Cardiovascular Diseases, Cause of Death, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Dose-Response Relationship, Drug, Female, Glucosides, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Placebos, Risk Factors, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.